Optimal treatment of actinic keratosis

Clinical Interventions in Aging

Volumn 9, Issue , 2013, Pages 15-16

  Goldenberg, Gary ^a  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DICLOFENAC; FLUOROURACIL; IMIQUIMOD; INGENOL MEBUTATE;

ACTINIC KERATOSIS; CRUSTING; DEPIGMENTATION; FLAKING; HUMAN; LETTER; LOCAL SKIN REACTION; LOCALIZED CHANGE IN PIGMENTATION; LOCALIZED ERYTHEMA; MINIMAL CHANGE IN PIGMENTATION; PIGMENT DISORDER; SCALING; SCAR FORMATION; TREATMENT PLANNING; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT;

HUMANS; KERATOSIS, ACTINIC; PRECANCEROUS CONDITIONS;

EID: 84890212411     PISSN: 11769092     EISSN: 11781998     Source Type: Journal    
DOI: 10.2147/CIA.S54426     Document Type: Letter

References (6)

1. Uhlenhake EE. Optimal treatment of actinic keratoses. Clin Interv Aging. 2013;8:29-35.
2. Lebwohl M, Swanson N, Anderson LL, Melgaard A, Xu Z, Berman B. Ingenol mebutate gel for actinic keratosis. N Engl J Med. 2012;366(11):1010-1019.
3. Picato (ingenol mebutate) gel 0.015%, 0.05% [package insert]. Parsippany, NJ: LEO Pharma Inc; 2012.
4. Aldara (imiquimod) cream, 5% [package insert]. Scottsdale, AZ: Medicis, The Dermatology Company; 2012.
5. Zyclara (imiquimod) cream 2.5%, 3.75% [package insert]. Scottsdale, AZ: Medicis, The Dermatology Company; 2012.
6. Efudex (fluorouracil) 5% cream [package insert]. Costa Mesa, CA. Valeant Pharmaceuticals North America; 2006.